Ultragenyx Pharmaceutical Inc.
RARE - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.59B
Close$
$55.30
222.2% upside
Current Fair Value
222.2% upsideUndervalued by 222.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.59 Billion |
|---|---|
| Enterprise Value | $1.54 Billion |
| Earnings per Share | $-5.83 |
| Beta | 0.32 |
| Outstanding Shares | 101,900,000 |
Return
| Return on Equity | 201.52% |
|---|---|
| Return on Assets | -46.39% |
| Return on Invested Capital | -56.67% |
Valuation & Multiples
| P/E Ratio | -2.76 |
|---|---|
| PEG | 13.81 |
| Price to Sales | 2.45 |
| Price to Book Ratio | -5.72 |
| Enterprise Value to Revenue | 2.15 |
| Enterprise Value to EBIT | -2.97 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | -0.26 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 3, 2026
EPS Estimate
$-1.10
Consensus analyst estimateRevenue Estimate
$182.49 M
Consensus analyst estimateNext Earnings Call
Expected Date
February 11, 2027
EPS Estimate
$-0.23
Consensus analyst estimateRevenue Estimate
$221.84 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 119.31% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.45%▼ 104.01% |
|---|---|
| Total Invested | $22.14M▼ 99.38% |
| Investors Holding | 48▼ 281.00% |
About Ultragenyx Pharmaceutical Inc.
CEO: Emil Kakkis
